Short answer
OMNICELL, INC. (OMCL) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $310M (up 14.9% year over year) with net income of $11M.
Q1 2026 key financials · XBRL
- Revenue
- $310M
- +14.9% YoY
- Net income
- $11M
- +261.7% YoY
- Operating margin
- 5.4%
- Gross margin
- 45.3%
- EPS (diluted)
- $0.25
- +266.7% YoY
Source: XBRL data from the OMNICELL, INC. (OMCL) Q1 2026 10-Q on SEC EDGAR. USD.
OMNICELL, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $309.9M, up 15% YoY from $269.7M
- Product revenue $174.8M, up 20% YoY, driven by automated dispensing systems and XTExtend
- Robotics revenue declined, including Central Pharmacy Dispensing and IV Compounding products
- Service revenue $135.1M, up 8% YoY from $124.5M
- Tariffs, labor shortages, Medicaid reductions, and health-system liquidity pressures as near-term headwinds
Risk Factors
- No risk-factors section provided; excerpt covers Items 2–6 only
- Executive trading-plan activity: Njoku plan covers up to 17,049 shares
- CEO Lipps new plan covers 10,000 shares plus 287,888 stock options
- Lipps terminated prior Rule 10b5-1 plan on February 23, 2026
- No share repurchases during quarter ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMNICELL, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.